Corporate | 20 September 2007 13:07
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Restructure of Company
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 20 September 2007 – As part of its acquisition of former MC Pharma
GmbH (now Eckert & Ziegler EURO PET Köln-Bonn GmbH), Eckert & Ziegler AG
(ISIN DE0005659700) increased its share of Eckert & Ziegler f-con Europe
GmbH from 51% to 61% and decided to restructure its cyclotron product
division. In the course of this change, Axel Schmidt will assume
responsibility for all the Group's cyclotron products and Kathleen Siegert
will be appointed a new managing director of the Eckert & Ziegler f-con
Europe GmbH division holding. She succeeds the transitional managing
director Ron Littmann. Executive Board chairman Dr. Andreas Hey, who was in
charge of establishing the Radiopharmaceuticals segment over recent years,
will not be renewing his contract and will leave the Group as of 31
December 2007. His responsibilities will be assumed by Dr. Andreas Eckert
until further notice.
The production and sales of radioactive contrast agents for PET scans
(Positron Emission Tomography), an imaging process for diagnosing various
types of cancer, are distributed among different regional subsidiaries and
share companies within the Group. Thus far they have not been under a
single management. In the new structure, responsibilities will be
centralized Europe-wide and processes reordered. The Group thereby expects
to achieve greater customer proximity, reduced need for internal
coordination, and higher profitability. It anticipates a net profit for the
cyclotron product division and sales of ten million euros for the first
time in 2008.
In addition to cyclotron products, the Radiopharmaceuticals segment of
Eckert & Ziegler AG includes systems and automation technology for
radiopharmaceutical production. Marketed under the 'Modular Lab' brand
name, these systems will not be affected by the restructuring measures.
The Executive Board
Your contact:
Eckert & Ziegler AG
Thomas Scheuch, Investor Relations, Robert-Rössle-Str. 10, D-13125 Berlin
phone: +49 (0) 30 / 94 10 84-139; fax: -112; e-mail:
thomas.scheuch@ezag.de, www.ezag.de
20.09.2007 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------